GXI Stock Analysis: Gerresheimer | XETRA
Medical Instruments & Supplies | XETRA, Germany | Market Cap: 929m EUR | 12M Return: -25.5% | DE000A0LD6E6 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.12M
Qual. Beats: -1
Rev. Trend: 93.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Gerresheimer AG is a Düsseldorf-based manufacturer of pharmaceutical packaging, drug delivery devices, and specialty glass and plastic containers. Founded in 1864, the company operates through three divisions - Plastics & Devices, Primary Packaging Glass, and Advanced Technologies - producing prefillable syringes, vials, ampoules, cartridges, bottles, inhalers, and auto- and pen-injectors.
In addition to its pharmaceutical and biotech core, Gerresheimer supplies diagnostic and medical disposables (such as point-of-care tests, infusion sets, and lancing devices), as well as cosmetic and food-and-beverage packaging. Its products are sold to pharmacy chains, supermarkets, and wholesalers across Germany and international markets. The company also maintains a strategic collaboration with Newel Health focused on integrated digital therapies for pharma clients.
Within the healthcare equipment sub-industry, Gerresheimer operates in a regulated, high-barrier-to-entry niche where customer relationships and quality certifications (such as GMP compliance) are critical competitive advantages. Demand for its products is structurally supported by the growth of biologics, self-administered injectables, and patient-friendly drug delivery formats, while its diversified end-markets - spanning pharma, diagnostics, cosmetics, and food and beverage - help offset cyclical exposure in any single segment.
- Biologics and GLP-1 demand accelerates prefillable syringe orders
- Energy cost inflation squeezes Primary Packaging Glass margins
- Auto-injector pipeline wins drive Plastics & Devices growth
| Net Income: -320.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 1.20 > 1.0 |
| NWC/Revenue: -11.12% < 20% (prev 0.33%; Δ -11.45% < -1%) |
| CFO/TA 0.05 > 3% & CFO 209.5m > Net Income -320.3m |
| Net Debt (1.53b) to EBITDA (312.9m): 4.88 < 3 |
| Current Ratio: 0.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (34.5m) vs 12m ago 0.0% < -2% |
| Gross Margin: 18.32% > 18% (prev 29.85%; Δ -11.53% > 0.5%) |
| Asset Turnover: 55.91% > 50% (prev 53.45%; Δ 2.46% > 0%) |
| Interest Coverage Ratio: -2.14 > 6 (EBIT TTM -209.3m / Interest Expense TTM 97.8m) |
| A: -0.06 (Total Current Assets 1.10b - Total Current Liabilities 1.36b) / Total Assets 4.49b |
| B: 0.20 (Retained Earnings 907.0m / Total Assets 4.49b) |
| C: -0.05 (EBIT TTM -209.3m / Avg Total Assets 4.15b) |
| D: 0.32 (Book Value of Equity 1.08b / Total Liabilities 3.39b) |
| Altman-Z'' = 0.28 = B |
| DSRI: 0.74 (Receivables 342.6m/404.3m, Revenue 2.32b/2.04b) |
| GMI: 1.63 (GM 29.85% / 18.32%) |
| AQI: 0.99 (AQ_t 0.34 / AQ_t-1 0.34) |
| SGI: 1.14 (Revenue 2.32b / 2.04b) |
| TATA: -0.12 (NI -320.3m - CFO 209.5m) / TA 4.49b) |
| Beneish M = -2.58 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at EUR 26.04 with a total of 92,375 shares traded. Over the past week, the price has changed by -3.20%, over one month by +1.80%, over three months by -1.44% and over the past year by -25.48%.
Current recommended Stop Loss: 23.90 (which is 8.2% or 2 ATR below the current price).
Gerresheimer has no consensus analysts rating.
P/E Forward = 9.9108
P/S = 0.4003
P/B = 0.8753
P/EG = 1.2325
Revenue TTM = 2.32b EUR
EBIT TTM = -209.3m EUR
EBITDA TTM = 312.9m EUR
Long Term Debt = 1.52b EUR (from longTermDebt, last quarter)
Short Term Debt = 549.5m EUR (from shortLongTermDebt, last quarter)
Debt = 1.70b EUR (from shortLongTermDebtTotal, last quarter) + Leases 104.3m
Net Debt = 1.53b EUR (calculated: Debt 1.70b - CCE 176.2m)
Enterprise Value = 2.46b EUR (929.1m + Debt 1.70b - CCE 176.2m)
Interest Coverage Ratio = -2.14 (Ebit TTM -209.3m / Interest Expense TTM 97.8m)
EV/FCF = -24.87x (Enterprise Value 2.46b / FCF TTM -98.8m)
FCF Yield = -4.02% (FCF TTM -98.8m / Enterprise Value 2.46b)
FCF Margin = -4.26% (FCF TTM -98.8m / Revenue TTM 2.32b)
Net Margin = -13.80% (Net Income TTM -320.3m / Revenue TTM 2.32b)
Gross Margin = 18.32% ((Revenue TTM 2.32b - Cost of Revenue TTM 1.90b) / Revenue TTM)
Gross Margin QoQ = 0.28% (prev 24.77%)
Tobins Q-Ratio = 0.55 (Enterprise Value 2.46b / Total Assets 4.49b)
Interest Expense / Debt = 5.74% (Interest Expense 97.8m / Debt 1.70b)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -157.0m (EBIT -209.3m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 0.81 (Total Current Assets 1.10b / Total Current Liabilities 1.36b)
Debt / Equity = 1.58 (Debt 1.70b / totalStockholderEquity, last quarter 1.08b)
Debt / EBITDA = 4.88 (Net Debt 1.53b / EBITDA 312.9m)
Debt / FCF = -15.47 (negative FCF - burning cash) (Net Debt 1.53b / FCF TTM -98.8m)
Total Stockholder Equity = 1.36b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.72% (Net Income -320.3m / Total Assets 4.49b)
RoE = -23.57% (Net Income TTM -320.3m / Total Stockholder Equity 1.36b)
RoCE = -7.27% (EBIT -209.3m / Capital Employed (Equity 1.36b + L.T.Debt 1.52b))
RoIC = -5.20% (negative operating profit) (NOPAT -157.0m / Invested Capital 3.02b)
WACC = 5.74% (E(929.1m)/V(2.63b) * Re(8.39%) + D(1.70b)/V(2.63b) * Rd(5.74%) * (1-Tc(0.25)))
Discount Rate = 8.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.0 | Cagr: 0.0%
[DCF] Fair Price = unknown (Cash Flow -98.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: 93.04 | Revenue CAGR: 6.42% | SUE: 0.34 | # QB: 0
EPS current Year (2026-11-30): EPS=2.21 | Chg30d=-2.36% | Revisions=-17% | GrowthEPS=+217.9% | GrowthRev=+1.5%
EPS next Year (2027-11-30): EPS=1.77 | Chg30d=-9.19% | Revisions=-50% | GrowthEPS=+926.2% | GrowthRev=+3.2%
[Analyst] Revisions Ratio: -44% (up=1, down=5)